Industry
Biotechnology
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 5:07 pm
Portfolio Pulse from Benzinga Insights
June 17, 2024 | 4:31 pm
Portfolio Pulse from Avi Kapoor
June 17, 2024 | 4:16 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 2:32 pm
Portfolio Pulse from Vandana Singh
June 17, 2024 | 1:52 pm
Portfolio Pulse from Avi Kapoor
June 17, 2024 | 1:40 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 12:33 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 12:25 pm
Portfolio Pulse from Benzinga Newsdesk
June 06, 2024 | 1:53 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 2:58 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.